Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 128, Issue 6, 2013, Pages

  Kuhle, J ^a,b   Malmestrom C ^c   Axelsson, M ^c   Plattner, K ^a   Yaldizli, Ö ^a   Derfuss, T ^a   Giovannoni, G ^b   Kappos, L ^a   Lycke, J ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cerebrospinal fluid; Multiple sclerosis; Natalizumab; Neurofilament heavy chain; Neurofilament light chain

Indexed keywords

BIOLOGICAL MARKER; NATALIZUMAB;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DISABILITY; DISEASE ACTIVITY; HUMAN; IMMUNOASSAY; MULTIPLE SCLEROSIS; NEUROFILAMENT HEAVY CHAIN; NEUROFILAMENT LIGHT CHAIN; NEUROFILAMENT PROTEIN; REMISSION;

CEREBROSPINAL FLUID; MULTIPLE SCLEROSIS; NATALIZUMAB; NEUROFILAMENT HEAVY CHAIN; NEUROFILAMENT LIGHT CHAIN;

ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; STATISTICS, NONPARAMETRIC;

EID: 84886640428     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12151     Document Type: Article

References (13)

1. Lee MK, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci 1996;19:187-217.
2. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-4.
3. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;61:1720-5.
4. Teunissen CE, Iacobaeus E, Khademi M et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322-9.
5. Kuhle J, Leppert D, Petzold A et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011;76:1206-13.
6. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005;4:510-8.
7. Norgren N, Karlsson JE, Rosengren L, Stigbrand T. Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics 2002;21:53-9.
8. Gunnarsson M, Malmestrom C, Axelsson M et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2010;69:83-9.
9. Kuhle J, Regeniter A, Leppert D et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 2010;220:114-9.
10. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-98.
11. Lee MK, Xu Z, Wong PC, Cleveland DW. Neurofilaments are obligate heteropolymers in vivo. J Cell Biol 1993;122:1337-50.
12. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004;63:1586-90.
13. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-8.